前沿生物2020年首次公开发行发行费用(不含增值税)总额为12,688.99万元，其中，承销及保荐费用为 11,612.51万元。 保荐机构相关公司UBSAG参与本次发行战略配售，获配股票数量为2,926,829股，占本次发行总量的 3.25%，获配金额59,999,994.50元。UBSAG本次跟投获配股票的限售期为24个月，限售期自本次公开发 行的股票在上交所上市之日起开始计算。 前沿生物实际控制人为DONGXIE(谢东)，美国国籍，拥有中国永久居留权。 中国经济网北京9月17日讯前沿生物(688221.SH)今日收报14.90元，跌幅1.97%，总市值55.81亿元。目前 该股处于破发状态。 前沿生物于2020年10月28日在上交所科创板上市，本次发行股份数量为8,996万股，占本次发行后总股 本的25.01%，全部为公开发行新股，发行价格为20.50元/股，保荐机构(主承销商)为瑞银证券有限责任 公司，保荐代表人为崔健民、严鹏举，联席主承销商为中信证券股份有限公司。 前沿生物上市当日最高报35.53元，为该股上市以来的股价最高峰。 前沿生物发行募集资金总额为184,418.00万元，募集资金净额为17 ...

中国经济网北京9月5日讯前沿生物(688221.SH)今日收报15.82元，跌幅16.34%。目前该股处于破发状 态。 前沿生物于2020年10月28日在上交所科创板上市，本次发行股份数量为8,996万股，占本次发行后总股 本的25.01%，全部为公开发行新股，发行价格为20.50元/股，保荐机构(主承销商)为瑞银证券有限责任 公司，保荐代表人为崔健民、严鹏举，联席主承销商为中信证券股份有限公司。 前沿生物实际控制人为DONGXIE(谢东)，美国国籍，拥有中国永久居留权。 2022年9月22日，前沿生物发布的以简易程序向特定对象发行股票上市公告书显示，本次发行数量 14,818,653股，发行价格13.51元/股。前沿生物本次发行募集资金总额为人民币200,200,002.03元，扣除 不含税发行费用人民币4,533,246.49元，募集资金净额为人民币195,666,755.54元。2022年9月5日，中信 证券将扣除保荐机构(主承销商)保荐承销费(含税)3,889,422.63元后的上述认购资金的剩余款项划转至发 行人就本次发行开立的募集资金专项存储账户中。 经计算，前沿生物上述两次募资共20.44亿元。 ...

前沿生物上市当日最高报35.53元，为该股上市以来的股价最高峰。 （责任编辑：马欣） 前沿生物首次公开发行股票募集资金总额为184,418.00万元，募集资金净额为171,729.01万元。前沿生物 于2020年10月22日披露的招股说明书显示，该公司拟募集资金200,085.00万元，计划用于1,000万支注射 用HIV融合抑制剂项目、艾可宁+3BNC117联合疗法临床研发项目、新型透皮镇痛贴片AB001临床研发 项目、营销网络建设项目、补充流动资金。 前沿生物首次公开发行股票的发行费用（不含增值税）总额为12,688.99万元，其中，承销及保荐费用为 11,612.51万元。 2018年至2024年，前沿生物实现归属于上市公司股东的净利润分别为-2.47亿元、-1.92亿元、-2.31亿 元、-2.60亿元、-3.57亿元、-3.29亿元和-2.01亿元，实现归属于上市公司股东的扣除非经常性损益的净 利润分别为-1.67亿元、-2.02亿元、-2.40亿元、-3.11亿元、-3.99亿元、-3.55亿元和-3.27亿元。 经计算，前沿生物上述两次募资共20.44亿元。 前沿生物于2020年10月28日在上 ...

Core Viewpoint - Frontline Bio (688221.SH) is currently trading at 19.63 yuan, reflecting a decline of 1.90% and is in a state of post-IPO price drop [1] Group 1: IPO Details - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital post-issuance, at a price of 20.50 yuan per share [1] - The total funds raised from the IPO amounted to 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the development of an HIV fusion inhibitor, clinical research for a combined therapy, and marketing network construction [2] Group 2: Financials and Shareholder Information - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3] - In a subsequent issuance on September 22, 2022, Frontline Bio issued 14.818 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.2 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total amount raised from both fundraising rounds is approximately 2.044 billion yuan [4]

Group 1 - The core point of the news is that 前沿生物 (Frontier Biotech) is currently experiencing a decline in stock price, with a closing price of 20.07 yuan and a drop of 7.55% [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) of 89.96 million shares, accounting for 25.01% of the total shares post-issue, at a price of 20.50 yuan per share [1] - The highest stock price recorded since the IPO was 35.53 yuan, indicating that the stock is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - On September 22, 2022, Frontier Biotech announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [2] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [2] - The total fundraising from both the IPO and the subsequent issuance amounts to approximately 2.044 billion yuan [3]

Core Viewpoint - Frontline Bio has reported a net loss for seven consecutive years since its IPO in 2020, with a peak fundraising of 1.8 billion yuan through UBS Securities [1][4]. Financial Performance - In 2024, the company achieved total revenue of 129.47 million yuan, representing a year-on-year increase of 13.32% compared to 114.25 million yuan in the previous year [1][3]. - The net profit attributable to the parent company was -202.02 million yuan, and the net profit after deducting non-recurring gains and losses was -336.19 million yuan [1][3]. - For 2023, the company reported total revenue of 114 million yuan, a year-on-year increase of 34.82%, with a net profit of -329 million yuan, slightly improved from -357 million yuan in the previous year [3][4]. Historical Financial Data - From 2018 to 2022, the company's revenue figures were 1.91 million yuan, 20.86 million yuan, 46.62 million yuan, 40.50 million yuan, and 84.74 million yuan, respectively [4]. - The net profits for the same period were -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, and -357 million yuan, indicating a consistent trend of losses [4]. IPO and Fundraising - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial share price of 20.50 yuan, raising a total of 1.84 billion yuan [4][5]. - The funds raised were intended for various projects, including clinical research for HIV treatments and pain relief patches, as well as for marketing network development and working capital [5].